结直肠癌中的巨噬细胞:恶性肿瘤标志物及有前景的治疗靶点
macrophages in colorectal cancer: Markers of malignancy and promising therapeutic targets.
作者信息
Xie Zhenyu, Zheng Gaozan, Niu Liaoran, Du Kunli, Li Ruikai, Dan Hanjun, Duan Lili, Wu Hongze, Ren Guangming, Dou Xinyu, Dai Songchen, Feng Fan, Zhang Jian, Zheng Jianyong
机构信息
Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Medical University, Xi'an, Shaanxi 710032, China.
Xi'an Medical University, Xi'an, Shaanxi 710021, China.
出版信息
Genes Dis. 2024 May 30;12(3):101340. doi: 10.1016/j.gendis.2024.101340. eCollection 2025 May.
macrophages have been identified as key players in the colorectal cancer (CRC) tumor microenvironment, but their function remains unclear. This study integrated single-cell and spatial transcriptomics with bulk sequencing to investigate the roles and mechanisms of macrophages in CRC. Our findings revealed a pronounced elevation of macrophages in CRC, especially within tumor territories. These macrophages served as markers for CRC initiation, progression, metastasis, and potential prognosis. Furthermore, they showed heightened transcriptional activity in genes linked to angiogenesis, epithelial-mesenchymal transition, glycolysis, hypoxia, and immunosuppression. protein amplified CRC cell migration and invasion, potentially mediating cellular crosstalk via the , , and complex axes. Patients with a high proportion of macrophages could benefit more from immune checkpoint blockade therapy. Interestingly, expression was significantly enriched in macrophages versus macrophages, possibly explaining limited anti-CSF1R monotherapy effects. In conclusion, we propose an macrophage model in CRC, highlighting such macrophages as a promising therapeutic target due to their malignancy markers.
巨噬细胞已被确定为结直肠癌(CRC)肿瘤微环境中的关键参与者,但其功能仍不清楚。本研究将单细胞和空间转录组学与批量测序相结合,以研究巨噬细胞在CRC中的作用和机制。我们的研究结果显示,CRC中巨噬细胞显著升高,尤其是在肿瘤区域内。这些巨噬细胞可作为CRC起始、进展、转移和潜在预后的标志物。此外,它们在与血管生成、上皮-间质转化、糖酵解、缺氧和免疫抑制相关的基因中表现出增强的转录活性。蛋白质增强了CRC细胞的迁移和侵袭能力,可能通过 、 和 复合体轴介导细胞间的相互作用。巨噬细胞比例高的患者可能从免疫检查点阻断治疗中获益更多。有趣的是,与 巨噬细胞相比, 表达在 巨噬细胞中显著富集,这可能解释了抗CSF1R单药治疗效果有限的原因。总之,我们提出了CRC中的 巨噬细胞模型,强调这类巨噬细胞因其恶性标志物而有望成为治疗靶点。